Mycamine
micafungin sodium
Treatment for Esophageal Candidiasis, Fungal Infection ProphylaxisFujisawa Healthcare, Inc. Submits NDA For Mycamine For Treatment Of Esophageal Candidiasis
Deerfield, Ill., April 27, 2004-- Fujisawa Healthcare, Inc. (Fujisawa) announced today that a New Drug Application (NDA) has been submitted to the U.S. Food and Drug Administration (FDA) for their investigational antifungal product to be marketed in the U.S. under the name Mycamine (micafungin sodium). With the submission of the NDA, Fujisawa seeks approval of micafungin for the treatment of esophageal candidiasis.
Micafungin is a member of a new class of antifungal agents, the echinocandins, which inhibit cell-wall synthesis. The novel mechanism of action of echinocandins specifically targets the wall of fungal cells to treat the infection.
About Esophageal Candidiasis
Esophageal candidiasis is a fungal infection located deep below the
throat. It is most commonly seen in immuno-compromised patients.
Approximately 10% of the U.S. AIDS population will have at least
one episode of esophageal candidiasis. Symptoms of esophageal
candidiasis can include chest pains and difficulty swallowing.
Treating the presence of candidiasis in the esophagus, before it
moves past the gastrointestinal tract, is key in arresting the
progress of the fungus before it reaches more difficult to treat
areas such as the lungs, bloodstream and kidney.
About Fujisawa Healthcare, Inc.
Fujisawa Healthcare, Inc., headquartered in Deerfield, Ill.,
develops, manufactures, and markets proprietary pharmaceutical
products in the United States and abroad. Fujisawa Healthcare, Inc.
is a subsidiary of Fujisawa Pharmaceutical Co., Ltd. based in
Osaka, Japan. Fujisawa Pharmaceutical Co., Ltd., founded in 1894,
is a leading pharmaceutical manufacturer and is actively developing
its international operations in North America, Europe, and Asia.
Fujisawa Healthcare, Inc. established its presence in the
anti-fungal market with the launch of AmBisome (liposomal
amphotericin B) in 1997.
Additional information on Fujisawa Healthcare, Inc. and its products can be found on the Internet at www.fujisawa.com
Related Articles:
Mycamine Fujisawa Healthcare, Inc. - Treatment for Candida Infections - March 16, 2005
New Drug Applications Archive
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2005: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2004: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
